Amaravadi, 29 patient HCQ early treatment RCT: 60% improved recovery [p=0.13] https://c19p.org/amaravadi
copied to clipboard
Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a remotely conducted randomized clinical trial
et al., medRxiv, doi:10.1101/2021.02.22.21252228 (Preprint)
Tiny early-terminated 34 patient RCT for outpatient treatment showing faster recovery with treatment (not statistically significant). All patients recovered (3 control patients recovered after crossover to the treatment arm). There was no mortality and only one hospitalization on day 0 before treatment. There were no severe adverse events.
|
risk of not reaching lowest symptom score at day 7 mid-recovery, 60.0% lower, RR 0.40, p = 0.13, treatment 3 of 15 (20.0%), control 6 of 12 (50.0%), NNT 3.3.
|
|
relative time to first occurrence of lowest symptom score, 42.9% lower, relative time 0.57, p = 0.21, treatment 15, control 12.
|
|
relative time to release from quarantine, 27.3% lower, relative time 0.73, p = 0.28, treatment 16, control 13.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Amaravadi et al., 2/26/2021, Double Blind Randomized Controlled Trial, USA, North America, preprint, 20 authors, dosage 400mg bid days 1-14.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.